What Figral Treats: Main Uses and Benefits

Figral is a medicine that is commonly used across conditions presenting with acute episodes of symptomatic discomfort. It is relevant when short-term symptomatic assistance is needed to address specific functional challenges. Its primary therapeutic role is to provide supportive relief when symptoms interfere with routine activities.

The medicine is used in situations involving specific distressing symptoms, including those associated with physical discomfort and heightened physiological activity. Figral is often applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms interfere with routine activities.

---

Easing Episodic Symptom Discomfort

Figral may assist with situations involving symptoms associated with acute or episodic changes. It is applied during phases of increased distress or discomfort, providing support that helps ease the overall symptom burden related to temporary functional strain. This use is in contexts where additional symptomatic support is needed.

Quick Fact: Addressing Symptoms of Functional Strain
Figral is commonly used in contexts where symptoms lead to temporary functional strain or discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Figral (Sildenafil) is designated for use by adult male patients and is subject to strict eligibility rules based on regulatory standards. The medicine is not indicated for individuals under 18 years of age or for women, as per the official label.

Contraindicated Populations (Must Not Use)

Use is strictly prohibited in patients with the following conditions or circumstances:

Contraindication Entity	Restriction Basis
Concomitant use of Organic Nitrates or Nitric Oxide Donors	Absolute regulatory exclusion
Concomitant use of Guanylate Cyclase Stimulators (e.g., Riociguat)	Absolute regulatory exclusion
Severe Cardiovascular Disorders (e.g., severe cardiac failure, unstable angina)	Where sexual activity is medically inadvisable
Recent Stroke or Myocardial Infarction (within the last 6 months)	Medical history limitation
Severe Hepatic Impairment or Resting Hypotension ( BP <90/50 mmHg)	Organ function or hemodynamic status
Vision loss due to NAION or Hereditary Retinal Disorders	Specific ocular conditions

Restricted or Conditional Use

Regulatory documents mandate special consideration or caution for the following populations, often requiring a lower starting dose:

• Severe Renal Impairment ( Creatinine Clearance <30 mL/min): A lower starting dose should be considered.
• Hepatic Impairment (Mild to Moderate): A lower starting dose should be considered.
• Geriatric Use (ge 65 years old): A lower starting dose should be considered due to reduced clearance.
• Anatomical Deformation of the Penis or conditions predisposing to priapism: Use with caution is advised.

Official eligibility rules prioritize patient safety by excluding specific groups based on drug interactions, severe pre-existing diseases, or physiological limitations, thereby defining the boundary for appropriate use.

Interactions with other medicines and products

The interaction profile of Figral, containing the active ingredient Sildenafil, is defined by strict regulatory guidelines regarding pharmacodynamic potentiation and metabolic clearance. The most critical interaction is the contraindication with Organic Nitrates (such as nitroglycerin) and Guanylate Cyclase (GC) Stimulators (such as riociguat). This prohibition is due to the potential for severe, life-threatening hypotension.

Documented Exposure Modification

Sildenafil is primarily cleared through the hepatic enzyme CYP3A4. Consequently, co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) significantly increases Sildenafil’s plasma exposure. For instance, the maximum single dose of Sildenafil must not exceed 25 mg within a 48-hour period when taken with ritonavir, as stated in prescribing information. Conversely, strong CYP3A4 inducers, such as bosentan, may reduce Sildenafil exposure.

Other Pharmacodynamic and Food Effects

Other regulatory constraints exist for concomitant use with Alpha-Blockers (e.g., doxazosin). The patient must be stable on the alpha-blocker therapy, and Sildenafil should be initiated at the lowest available dose (25 mg) due to the risk of additive hypotensive effects. A documented food interaction shows that a high-fat meal delays the rate of absorption and reduces the maximum plasma concentration of the medicine.

Targeting the PDE5 Enzyme and the cGMP Pathway

Figral's mechanism is defined by the selective competitive inhibition of a specific enzyme, resulting in localized modulation of vascular smooth muscle. The core mechanism involves the active ingredient, Sildenafil, targeting the Phosphodiesterase type 5 (PDE5) enzyme found in the smooth muscle cells of certain blood vessels. Sildenafil acts as an inhibitor by blocking PDE5 from breaking down the signaling molecule cyclic Guanosine Monophosphate (cGMP). This direct molecular interaction preserves cGMP, the substance necessary for initiating smooth muscle relaxation.

---

Potentiation of Local Physiological Response

The preservation of cGMP results in the potentiation of the natural Nitric Oxide (NO) pathway. The drug's mechanism is contingent upon the local release of NO, which is required for cGMP synthesis. By preventing cGMP's destruction, Figral enhances and prolongs the body’s own signal for relaxation. This sustained molecular effect results in a reduction of tension within the blood vessel walls.

---

Modulating Vascular Tone and Blood Flow

The direct physiological consequence of sustained cGMP and smooth muscle relaxation is the modulation of vascular tone. This leads to vasodilation, a localized widening of the blood vessels where the enzyme is present. The resulting reduction in vascular resistance facilitates an increase in local blood flow into the target tissue, a key physiological consequence of the mechanism.

How to Use Figral (Sildenafil) — Official Administration Guidelines

Figral contains the active ingredient sildenafil, and its official use protocol is strictly dependent on the condition being addressed. The following details outline the standard administration parameters for the medication.

---

Official Dosage Forms and Routes

Sildenafil is approved for administration by two primary routes: oral (film-coated tablets, reconstituted oral suspension) and intravenous (IV) injection.

Dosing Regimen and Frequency

The standard dosage and frequency differ significantly by purpose:

Purpose	Standard Adult Starting Dose	Frequency	Timing Constraint
Erectile Dysfunction (ED)	50 mg (Oral)	As needed, maximum once per day	Taken 30 minutes to 4 hours before activity
Pulmonary Arterial Hypertension (PAH)	20 mg (Oral) or 10 mg (IV)	Three times a day (TID)	Oral doses 4 to 6 hours apart

---

Contextual and Population-Specific Instructions

Food Intake: For ED treatment, the oral tablet can be taken with or without food, though a high-fat meal may delay the onset of activity.

Preparation: The oral suspension requires reconstitution with a specific volume of water and must be shaken well before each use. A calibrated measuring device must be employed for accurate dosing.

Dose Adjustment: Standard guidelines include the consideration of a reduced starting dose of 25 mg for ED patients who are elderly (≥ 65 years), have severe renal or hepatic impairment, or are concurrently taking certain potent enzyme inhibitors (e.g., strong CYP3A4 inhibitors). The dose should not exceed 25 mg within a 48-hour period when taken with ritonavir.

Research evidence / Overview of studies for Figral

Official research has explored the compound Sildenafil in specific conditions characterized by fluctuating or episodic manifestations and systemic imbalance. Evidence, primarily from regulatory-grade clinical trials, helps describe the patterns observed in these studied populations, contributing to the broader evidence landscape. The primary research for this compound consists of numerous controlled studies exploring symptom and functional axes over defined time intervals.

---

Evidence for Use in Erectile Dysfunction

The research base for this condition relies primarily on short-term, placebo-controlled, double-blind Randomized Controlled Trials (RCTs). These pivotal trials were applied in research contexts involving fluctuating or unstable symptoms, and they focused on monitoring outcomes related to systemic or functional imbalance in a broad population of adult males with varied underlying causes for their condition. Long-term open-label extension studies (up to 3 years) described the maintenance of outcomes related to daily functioning over intermediate time frames in the studied populations. Data show patterns related to measured differences during the study period when compared to baseline. However, research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

The evidence for this complex condition primarily involves short-term RCTs (lasting 12 to 16 weeks) that investigated dose-ranging effects, supported by long-term follow-up extension studies. The trials monitored outcomes reflecting daily functioning and physiological strain, such as the standardized Six-Minute Walk Distance (6MWD). Research examined how outcomes related to daily functioning were monitored in the observed populations, and studies reported patterns related to measured outcomes in walking distance compared to those receiving the placebo.

---

Understanding the Gaps: Areas of Uncertainty

Research provides context but not individual predictions. Several areas require further investigation or where the existing data has limitations. There is limited information for long-term outcomes beyond the few years covered in the extension studies for both primary indications. The results apply only to the populations studied; for instance, many trial participants in ED research had some baseline function, so findings for patients with the most severe functional limitations are uncertain.

Key Studies & References

1. Sildenafil Citrate Drug Information - MedlinePlus

Common questions about Figral (FAQ)

Q: Is Figral a common prescription or an over-the-counter medicine?

A: Figral, which contains the active ingredient Sildenafil, is strictly a prescription-only (Rx) medicine. This means it requires authorization from a healthcare professional and is not available to purchase over the counter.

Q: Does Figral interact with alcohol, and how severe is the interaction?

A: Regulatory information notes that caution is typically advised regarding alcohol use with Figral. Since Sildenafil can cause a drop in blood pressure, combining it with alcohol may further increase the risk of side effects like dizziness, lightheadedness, or fainting.

Q: Is Figral safe for older men (e.g., over 65)?

A: Regulatory labeling indicates that use in older men is permitted, but a reduced starting dose is often considered by healthcare providers for patients aged 65 years and older. This is due to the potential for the medicine to remain in the body longer in this age group.

Q: Are there different strengths or dosages of Figral available?

A: Yes, Figral is available in multiple strengths to accommodate different conditions and patient needs. The oral tablets for Erectile Dysfunction are commonly available in 25 mg, 50 mg, and 100 mg strengths, as noted in regulatory product information. Different strengths are used for other indications, such as Pulmonary Arterial Hypertension.

Q: How often is it safe to take Figral?

A: For the treatment of Erectile Dysfunction, official prescribing information states that Figral is taken as needed. The maximum recommended frequency in a 24-hour period is once, according to official prescribing information.

Q: Does Figral cause dependency if taken long-term?

A: Sildenafil, the active ingredient in Figral, is not classified as a controlled substance and is not considered a physically addictive or habit-forming medication. Regulatory research, which includes long-term extension studies, has focused on maintaining outcomes over time.

Q: Is it okay to cut Figral tablets in half?

A: Official labeling does not provide instructions for cutting or splitting the film-coated tablets. The tablets are typically intended to be taken whole to ensure the correct dosage and effectiveness.

Q: Can Figral be taken on a daily basis?

A: The appropriateness of taking Figral daily depends on the condition being addressed. For Erectile Dysfunction, the maximum recommended frequency is once per day. For the treatment of Pulmonary Arterial Hypertension (PAH), the dose is typically taken three times a day.

Q: What should I do if I suspect an allergic reaction to Figral?

A: Severe symptoms like sudden vision loss, hearing loss, or a prolonged erection (priapism) are rare but clinically serious and require immediate medical attention. Any suspected severe reaction warrants consulting a healthcare professional without delay.

Q: What's the main difference between Figral and Viagra?

A: Figral and Viagra contain the same active ingredient, Sildenafil. Figral is a specific brand name for this medication, while Viagra is the original brand name that was first approved by regulatory authorities for Sildenafil.

Q: What happens if I miss a dose of Figral?

A: Figral is taken 'as needed' for Erectile Dysfunction, so a dose cannot be missed in that context. The regulatory label does not provide specific instructions for a missed dose when taken regularly for Pulmonary Arterial Hypertension (PAH). Questions about missed doses for regular use should be directed to a healthcare provider.

Q: What happens if Figral is taken with grapefruit juice?

A: Official information notes that grapefruit and grapefruit juice may affect the metabolism of Figral. It is typically advised to avoid or limit their consumption, as they can raise the levels of Sildenafil in the body.

Q: Can Figral affect fertility or sperm quality?

A: Regulatory labeling does not provide detailed information about the effects of Sildenafil on human fertility or sperm quality. This area is not explicitly covered in the official patient-facing materials.

Q: Is Figral chemically similar to other ED treatments like Cialis or Levitra?

A: Yes, Figral (Sildenafil) belongs to the same class of medicines as Cialis (Tadalafil) and Levitra (Vardenafil). They are all categorized as Phosphodiesterase type 5 (PDE5) inhibitors, meaning they share a similar mechanism of action.

Q: Is Figral a controlled substance?

A: Figral (Sildenafil) is a prescription-only medicine but is not classified as a controlled substance by government drug enforcement agencies. This indicates it does not carry a high risk of abuse or dependence.

Q: Does Figral have any warnings about driving or operating machinery?

A: Yes, due to reported side effects such as dizziness or visual disturbances, regulatory information advises awareness of how Figral affects an individual before driving or operating machinery.

Q: Is it better to take Figral in the morning or at night?

A: For Erectile Dysfunction, Figral is taken based on timing relative to activity (30 minutes to 4 hours prior), not a specific time of day. For Pulmonary Arterial Hypertension (PAH), it is taken regularly three times a day, with doses spaced 4 to 6 hours apart.

Q: Does Figral require a special diet before or after use?

A: No special diet is required with Figral. However, regulatory documents note that consuming a high-fat meal may slow down the medicine's absorption rate, potentially delaying the time it takes to start working.

Q: What is the difference between brand-name Figral and its generic equivalent?

A: Brand-name Figral and its generic equivalent, Sildenafil, are required by regulatory agencies to contain the identical active ingredient and meet the same quality, strength, purity, and effectiveness standards.

Q: Are there any known side effects on mood or mental health from Figral?

A: While common side effects include physical effects like dizziness, official labeling does not specifically list mood changes. However, nervous system adverse events are documented, and any concerning psychological changes should be reported to a healthcare provider.

Q: What makes Figral distinct from Sildenafil?

A: Sildenafil is the name of the active drug ingredient itself. Figral is simply a specific brand name that a company uses for its pharmaceutical product containing sildenafil.

Q: Is it possible to develop a tolerance to Figral over time?

A: Regulatory research, including extension studies, has observed outcomes over time, but official patient information does not explicitly use the term 'tolerance' or 'tachyphylaxis' in reference to long-term use. The drug's mechanism of action remains consistent.

Q: Why do some people say Figral doesn't work for them?

A: Clinical trial data show that not every participant responds to the drug in the same way. Official research notes that outcomes can vary, with some patients reporting a lack of effectiveness, which can depend on individual circumstances and underlying medical conditions.

How to Store and Dispose of Figral

Official regulatory documents define strict requirements for storing and disposing of Figral (Sildenafil Citrate) to maintain its quality and ensure safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F to 77 F).
Packaging	Keep the tablets in the original container, tightly closed, to protect from moisture.
Child Safety	As with all medications, Figral must be kept out of the sight and reach of children.
Liquid Form	Reconstituted oral suspension must not be frozen and must be discarded 60 days after mixing.

Disposal Instructions

Unused or expired Figral should be disposed of using a drug take-back program as the preferred method. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds) in a sealed bag before being placed in the household trash.